Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursofalk 500 mg tablets versus Ursofalk 250 mg capsules in primary biliary cholangitis
2008-001524-31Phase 4Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jul 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoints: Relative change in alkaline phosphatase, Relative change in gamma-glutamyl transferase and 1 more. Started Jul 2008; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2008-001524-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001524-31.